Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / PGEN - Precigen regains exclusive rights to CAR-T treatment for cancer

PGEN - Precigen regains exclusive rights to CAR-T treatment for cancer

Precigen Inc.

2023-04-03 16:48:12 ET

  • Precigen ( NASDAQ: PGEN ) amended its exclusive license agreement with Alaunos Therapeutics to use UltraCAR-T platform for development and commercialization of two CAR-T targets, CD19 and B-cell maturation antigen, in order to bolster portfolio and broaden strategic opportunities.
  • Precigen is helping cancer centers to deliver personalized, autologous CAR-T treatment with overnight manufacturing for cancer patients.
  • The Company also regained exclusive rights to IL-12 gene therapy, including application through the AdenoVerse platform.
  • Press Release

For further details see:

Precigen regains exclusive rights to CAR-T treatment for cancer
Stock Information
Company Name: Precigen Inc.
Stock Symbol: PGEN
Market: NASDAQ
Website: precigen.com
Menu
PGEN PGEN Quote PGEN Short PGEN News PGEN Articles PGEN Message Board
Get PGEN Alerts

News, Short Squeeze, Breakout and More Instantly...